Endeavor BioMedicines’ Post

Researchers used our Nutragen® (6mg/ml collagen) for a "3D Fibroblast Collagen Contraction Assay." This was part of a study to better understand the role of RUNX1 in the fibrotic progression of the autoimmune disease Systemic Sclerosis. Dermal fibrosis is a clinical manifestation of Systemic Sclerosis, resulting from the uncontrolled deposition of extracellular matrix. This study is the first to demonstrate a potential role for RUNX1 in the pathogenesis of Systemic Sclerosis Dermal Fibrosis. Read the full publication here: https://lnkd.in/e8pCyNkk #cellculture #collagen #3D

Presented at the #ESMOSarcomaAndRareCancers24, the results from an expansion cohort of a phase I/II study reveal that the combination of irinotecan and lurbinectedin demonstrates efficacy in patients with pre-treated Grade 3 gastroenteropancreatic neuroendocrine carcinomas (GEP-NECs). For further insights on this subject, delve into the details in the #ESMODailyReporter. 👉https://ow.ly/kWqJ50QUXpW

As September’s Pulmonary Fibrosis Awareness Month comes to an end, our commitment at Boehringer Ingelheim to addressing unmet medical needs continues – not just for patients today, but for generations to come. Building on our heritage in this space, we have a deep understanding of pulmonary fibrosis, its heterogeneity, molecular pathways, biomarkers, and the mechanisms of fibrosis. Our ambition is to continue to lead the science and go beyond slowing progression, to hopefully restore health and to potentially prevent progression in early disease. We know we can’t do it alone. We are committed to forging partnerships and exploring new avenues to turn a brighter future into a tangible reality for patients. #PulmonaryFibrosis #ResearchandDevelopment

#DDW2024 Many thanks for the support of my supervisors Prof. Klaas Nico Faber, Prof. Gerard Dijkstra, and Prof. Hermie Harmsen as well as our technicians. We have tried to use the 'Human oxygen-Bacteria anaerobic' (HoxBan) system to co-culture primary human intestinal fibroblasts or organoid-derived epithelial monolayers with the fecal microbiome of CD patients with active or remissive disease to study host-microbe interactions. From our preliminary data, we found that the fecal microbiome of active CD patients induces cytotoxicity and inflammatory responses in vitro.

They write: PQ912, is currently undergoing clinic trials for the treatment of Alzheimer’s disease. We report an X-ray crystal structure of sQC complexed with PQ912, revealing that the benzimidazole makes “anchor” interactions with the active site zinc ion and catalytic triad. Structure-guided design and optimization led to a series of new benzimidazole derivatives exhibiting nanomolar inhibition for both sQC and gQC. In a MPTP-induced Parkinson’s disease (PD) mouse model, BI-43 manifested efficacy in mitigating locomotor deficits through reversing dopaminergic neuronal loss, reducing microglia, and decreasing levels of the sQC/gQC substrates, α-synuclein, and CCL2. This study not only offers structural basis and new leads for drug discovery targeting sQC/gQC but also provides evidence supporting sQC/gQC as potential targets for PD treatment.

These findings indicate that heart organoids serve as robust models for investigating heart disease, closely mirroring conditions observed in human hearts. They offer a promising alternative to animal testing in cardiovascular research, facilitating the evaluation of novel drugs and the identification of potential treatments. Read full article here: https://lnkd.in/gfbxYfsG Ready to elevate your cardiac research? Contact us today at info@gvrp.in to learn more about integrating NEXEL's hiPSC-derived cardiomyocytes into your studies. Discover the difference that heart organoids can make in your cardiac research. GV Research Platform (GVRP) is the authorised distributor of NEXEL's cell products and services in India. ........................... #organoids #animaltesting #preclinicalresearch #cardiovasculardiseases #cardiacdiseases #heartattack #drugdiscovery #drugdevelopment #advancedscience #researchanddevelopment

Dr. Frank Vicini, @Michigan Healthcare Professionals, discusses his #ASTRO23 oral presentation, exploring the impact of #DCISionRT, the 7-gene biosignature, on risk assessment for patients assessed as low-risk using clinicopathology (CP) criteria. Emphasizing the necessity for improved tools to discern those truly requiring radiation therapy (RT), Dr. Vicini notes that traditional CP factors have been insufficient to consistently identify patients suitable for RT de-escalation. Despite past efforts in prospective trials, a CP low-risk group with no RT benefit for local control has not been clearly identified. This study re-evaluates patients with low-risk CP using DCISionRT. Dr. Vicini concludes that the data reveals ~50% of patients labeled 'low-risk' by various CP criteria are actually deemed high risk by DCISionRT and benefited significantly from RT. Watch Dr. Vicini’s presentation  https://lnkd.in/gM4TpkM9  #bcsm #PreludeDx #BreastCancer

🌟 NEW EPISODE ALERT 🌟 Dive deep into the world of Idiopathic Pulmonary Fibrosis (IPF) with Dr. Victor Thannickal on our latest episode of BIO from the BAYOU. 🎙️ Learn about the symptoms, progression, and the groundbreaking drug therapies being developed to combat this devastating lung disease. 🔍 Highlights: • Understanding IPF fundamentals • Impact on patient lives • Innovative therapies from Dr. Thannickal’s lab • Latest research advancements 📲 Listen now and stay ahead in biotech developments! #Biotech #HealthcareInnovation #IPF #LungDisease #PharmaceuticalResearch ➡️ Listen to Episode 36 Now (link in comments)

John Tsai, MD, Forcefield CEO, featured in In Vivo’s roundup of industry leaders and experts’ predictions for biopharma in 2024. John predicts an increasing focus on therapies targeting areas of high unmet need for large disease populations, including for cardiovascular, metabolic and renal disease where there’s already been a surge of exciting innovation. At Forcefield we are excited to be working towards revolutionising the treatment of acute heart attacks, where there has been no significant pharmacological development in the past two decades. Read the full In Vivo article here: https://lnkd.in/ee3G86vA #biotech #cardiovasculardisease #heartdisease

💖 ❤️ Cardiac troponin (cTn) is a specific biomarker for myocardial cell injury, garnering increasing attention from clinicians in recent years due to its higher sensitivity and specificity in diagnosing acute myocardial infarction (AMI). 📌 But how much do we really understand about this important marker? 💭 Let's delve into the world of cardiac troponin together. 🔜 🧐 MORE:https://lnkd.in/g68B3s8X #Cardiactroponin #ivd #AMI